.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Queensland Health
Fish and Richardson
Argus Health
Novartis
Colorcon
Covington
Baxter
Harvard Business School

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,544,373

« Back to Dashboard

Which drugs does patent 7,544,373 protect, and when does it expire?


Patent 7,544,373 protects SOLODYN and XIMINO and is included in two NDAs. There have been four Paragraph IV challenges on Solodyn.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 7,544,373

Title:Minocycline oral dosage forms for the treatment of acne
Abstract:Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Briscoe, TX), Bhatia; Kuljit (Nesconset, NY), Patel; Bhiku (Chandler, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:11/695,539
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-002May 8, 2006DISCNYesNo7,544,373► SubscribeY
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-001Jul 11, 2012RXNoNo7,544,373► SubscribeY
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-003Jul 11, 2012RXNoNo7,544,373► SubscribeY
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-005Jul 11, 2012RXNoNo7,544,373► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,544,373

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,776Minocycline oral dosage forms for the treatment of acne► Subscribe
8,722,650Extended-release minocycline dosage forms► Subscribe
7,541,347Minocycline oral dosage forms for the treatment of acne► Subscribe
7,919,483Method for the treatment of acne► Subscribe
9,192,615Method for the treatment of acne and certain dosage forms thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,544,373

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2613273► Subscribe
China101208097► Subscribe
European Patent Office1898925► Subscribe
Israel188331► Subscribe
Japan2013213047► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Deloitte
Julphar
Harvard Business School
Cipla
Boehringer Ingelheim
Chubb
Teva
Farmers Insurance
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot